

Disclosure of Relevant Financial Relationships with Commercial Companies

The Hope Foundation endorses the Standards of the Accreditation Council for Continuing Medical Education and the Guidelines of the American Medical Association. The Hope Foundation requires that all presentations at CME activities be fair, balanced, free of commercial bias, and fully supported by scientific evidence.

Everyone who is in a position to control the content of a continuing medical education activity is required to disclose relevant relationships with commercial companies whose products or services are discussed in educational presentations. The ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Disclosure of a relationship is not intended to suggest bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

All potential conflicts of interest have been resolved prior to this program.

A. Financial Disclosures Related to CME Activities and Requirements:

<u>Planner/Faculty Member</u>	<u>Nature of Relationship</u>	<u>Company</u>
Manmeet Ahluwalia	Consultant	AZ, Abbvie, Karyopharm, VBI Vaccines, Flatiron, Varian Medical Systems
	Research Grant	Abbvie, AZ, BMS, Bauer, Merck, Novocure, Pharmacyclics, Incyte
	Stock/Shareholder	Mimivax, Doctible
	Other	Royalty from Wiley; Honorarium from Elsevier
Syed A. Ahmad	Speaker's Bureau	Abbvie
Banu Arun	Research Grant	Abbvie, PharmaMar, Invitae
	Other	Advisory role with AZ
Alan Ashworth	Consultant	AtlasMDX, Pfizer, Sun Pharma, Bluestar, Gladiator, Genentech, Prolynx, Tango
	Research Grant	Sun Pharma, AZ
	Stock/Shareholder	Syncona, Tango
	Other	Co-Founder Tango; holds patents on the use of PARP inhibitors held jointly with AZ
Marie Bakitas	No Disclosures	
Ana Barac	Speaker's Bureau	BMS
	Research Grant	Genentech
Julie Behm	No Disclosures	
Charles Blanke	No Disclosures	
Carolina Wienser Ceballos	No Disclosures	
Young Chae	Consultant	Genentech, Foundation Medicine, Bodesix, Roche, Guardant Health, Immuneoncina, Takeda
	Speaker's Bureau	AZ, Guardant Health
	Research Grant	Abbvie, BMS
Mark Chao	Stock/Shareholder	Forty Seven, Inc.
	Other	Employee/Co-Founder: Forty Seven, Inc.
Patrick Collier	No Disclosures	

Morgan Cox	No Disclosures	
John Crowley	No Disclosures	
Jig Deneve	No Disclosures	
Lee Ellis	Data Monitoring Committee	Roche
Harry Erba	Consultant Speaker's Bureau Honorarium	Agios, Amgen, Astellas, Celgene, Daiichi Sankyo, Incyte, Jazz, MacroGenics, Novartis, Pfizer Agios, Celgene, Incyte, Jazz, Novartis Covance
Jonathan Friedberg	Data Safety Monitoring Committee	Bayer, Astellas
Sarju Ganatra	No Disclosures	
David Gandara	Consultant Research Grant	AZ, Pfizer Roche-Genentech
Kenneth Grossman	Consultant	Array, BMS, Novartis, Genentech, Castle
Salim Hayek	No Disclosures	
Norah Lynn Henry	Research Grant	Pfizer, AbbVie, Innocrin Pharmaceuticals, AZ
Dawn Hershman	No Disclosures	
Johanna Horn	No Disclosures	
David Hui	Research Grant	Helsinn, Insys
Melinda Irwin	No Disclosures	
Lisa Kachnic	Honorarium Royalties	Epic UpToDate
Steven Katz	No Disclosures	
Deborah Keller	No Disclosures	
Karen Kelly	Consultant Research Grant Other	Abbvie, AZ, EMD Serono, Genentech, Merck, Pfizer, Regeneron Abbvie, EMD Serono, Genentech, Lycera, Transgene, Regeneron DSMC for AZ; Author Royalties for UpToDate; Honorarium from Merck
Anne Kirchhoff	No Disclosures	
Austin Kirchner	Research Grant	Astellas/Medivation, Brainlab, Inc., Novartis
Larissa Korde	No Disclosures	
Robert Krouse	No Disclosures	
Razelle Kurzrock	Consultant Speaker's Bureau Research Grant Other	NeoMed, Roche Roche Incyte, Genentech, Merck Serono, Sequenom, Foundation Medicine, Guardant Health, Konica Minolta, OmniSeq, MedImmune Share in IDbyDNA; Founder of CureMatch, Inc.
Andrew Lowy	No Disclosures	

Adam Margolin	Consultant	Sema4
Ginny Mason	No Disclosures	
Monica Mita	No Disclosures	
Halle Moore	Research Grant	PUMA and AbbVie
Marian Neuhouser	No Disclosures	
Peter O'Dwyer	Consultant Research Grant Other	Celgene, Genentech, Array Pfizer, Genentech, BMS, GSK, Five Prime, FortySeven, BBI, Novartis, Celgene, Incyte, Lilly/Imclone, Array, H3 Biomedicine Expert testimony: Bayer, Lilly
Robert Orlowski	No Disclosures	
Mark O'Rourke	No Disclosures	
Colette Pameijer	No Disclosures	
Sandip Pravin Patel	Consultant Research Grant	AstraZeneca, BMS, Nektar, Illumina, Tempus BMS, AZ, Fate, Merck, Pfizer, Roche/Genentech, Xcovery, Genocea, lovance
Lajos Pusztai	Consultant Research Grant	Merck, AZ, Almac Diagnostics, Novartis, Genentech, Eisai, Athenex L.P. Merck, AZ, Roche/Genentech, Seattle Genetics
James Rae	No Disclosures	
Scott Ramsey	Consultant Research Grant Advisory Board	Epigenomics Kite Pharmaceuticals, Genentech, BMS, AstraZeneca Bayer
Flavio Rocha	No Disclosures	
Lawrence Schwartz	Consultant DSMB Research Grant	Roche Novartis Merck, Lilly, Daiichi Sankyo
Heloisa Soares	Consultant	Ipsen, Novartis, Exelixis, Lexicon
Charles Staley	No Disclosures	
Virginia Sun	No Disclosures	
Paul Swiecicki	No Disclosures	
Ian Thompson	Consultant Honorarium	Partners Healthcare, Magforce, Profound Medical, Rapamycin Holdings Univ Miami Cancer Center, Fred Hutchinson Cancer Center, and Am. Urological Association
Esperanza Pena Torres	No Disclosures	
Lauren Wallner	No Disclosures	
Courtney Wille	No Disclosures	
Ignacio Wistuba	Consultant	Genentech/Roche, BMS, AS/Medimmune, Pfizer, HTG Molecular, Asuragen, Merck, GSK, MSD

	Speaker's Bureau	MSD, Genentech/Roche, Pfizer
	Honorarium	Medscape, Pfizer, Merck, MSD
	Research Grant	Genentech, HTG Molecular, DepArray, Merck, BMS, 4D, J&J, Bayer, Karus, Medimmune, Adaptive, Adaptimmune, EMD Serono, Pfizer, Takeda, Amgen, Bayer, Akoya
Adam Yopp	No Disclosures	

B. Financial Disclosures Related to Scientific Activities of SWOG

The relevant policy and process for disclosure of financial conflict of interest within SWOG are governed by Group Policy #35, "Financial Conflict of Interest Policy" (<http://swog.org/Visitors/Download/Policies/Policy35.pdf>) which was established in accordance with (and is consistent with) the Public Health Service regulation entitled "Responsibility of Applicants for promoting Objectivity in Research for which PHS Funding is Sought and Responsible Prospective Contractors" (42 CFR Part 50, 45 CFR 94, final rule published 8/25/2011). Policy #35 is made available to the public via the publicly accessible portion of SWOG's website. Federal regulations require that SWOG management plans be made available within 5 business days upon written request.